Paweł Roszczyk in XYZ: EUR 22 million invested in Italy and approximately EUR 350 million in Poland
After seven years of partnership, Adamed Pharma is taking control of the Italian company Ecupharma. The company has acquired an additional 60% stake for EUR 22 million, becoming its majority shareholder. The transaction will accelerate Adamed’s growth in the third-largest pharmaceutical market in the European Union. Paweł Roszczyk, Member of the Management Board and Managing Director of Adamed Pharma, discussed the company’s plans in an interview with Mariusz Bartodziej of XYZ.
Adamed has been associated with Ecupharma since 2019, when it acquired a 25% stake in the company. Including the latest transaction, Adamed has invested more than EUR 22 million in Ecupharma. The remaining 15% stake will be acquired in 2031.
As Paweł Roszczyk emphasised, this is a carefully considered model for building the company’s international presence.
“First, a partnership that provides knowledge and experience, followed by an informed investment with a lower level of risk,” he said.
Adamed followed a similar path in Vietnam. In 2017, the company acquired a majority stake in Davipharm. Six years later, it became the company’s sole owner.
Ecupharma is a family-owned company established in 1993. It has a nationwide sales network and employs approximately 100 people. The company’s founder, Luciano Grottola, will continue to lead the business.
Italy’s pharmaceutical market is almost three times larger than Poland’s. The country’s population is also ageing more rapidly, driving demand for value-added medicines, which are a key area of focus for Adamed. In 2019, the company also opened its own representative office in Italy. Adamed intends to operate in the country for decades under its own brand.
International expansion is an important pillar of Adamed’s growth. In 2026, international markets are expected to generate nearly EUR 300 million in revenue, accounting for approximately 45% of the Group’s total sales.
The company’s international growth is not taking place at the expense of its operations in Poland. Between 2020 and 2030, Adamed’s investments in Poland will total approximately EUR 350 million. Since 2020, the company has invested approximately EUR 177 million in the country, with a further approximately EUR 163 million planned for 2026–2030.
Most of these funds are being invested in Pabianice, where Adamed is developing, among other projects, a manufacturing facility for dry powder inhalers (DPI). The first products manufactured at the new facility are expected to become available in 2029.
Read the full interview on: https://xyz.pl/adamed-przejmuje-we-wloszech-za-100-mln-zl-w-polsce-inwestuje-15-mld-zl/